Improved survival of Korean patients with idiopathic pulmonary arterial hypertension after the introduction of targeted therapies.

Abstract

OBJECTIVES:

We compared the survival of patients with idiopathic pulmonary arterial hypertension (IPAH), receiving conventional and targeted therapies.

BACKGROUND:

IPAH is an incurable disease with high mortality. To manage IPAH, several targeted therapies have been used in Korea.

METHODS:

We performed a retrospective study of 71 patients diagnosed with IPAH in a tertiary hospital between January 1994 and February 2013. Patients were classified into "conventional therapy group" (treated with conventional therapies and/or beraprost) and "targeted therapy group" (treated with targeted therapies other than beraprost).

RESULTS:

The median age of the patients was 33 years and 50 patients were female. The survival rate at 1, 3, 5, and 10 years was 80.1% 62.0%, 51.5%, and 26.8%, respectively. The survival rate in the targeted therapy group was greater than in the conventional therapy group (p-value = 0.026).

CONCLUSIONS:

We believe targeted therapies would improve survival benefits in IPAH patients.

• Authors: Byung Ju Kang, Sang-Do Lee, Yeon-Mok Oh, Jae Seung Lee
• Journal: Heart & lung : the journal of critical care (Heart Lung) 2014 Nov-Dec Vol. 43 Issue 6 Pg. 561-8 ISSN: 1527-3288 [Electronic] United States
• PMID: 25151431 (Publication Type: Comparative Study, Journal Article)
• Copyright: Copyright © 2014 Elsevier Inc. All rights reserved.

Chemical References

• beraprost
• Epoprostenol

Topics

• Adult
• Epoprostenol (analogs & derivatives, therapeutic use)
• Familial Primary Pulmonary Hypertension (mortality, therapy)
• Female
• Humans
• Male
• Middle Aged
• Republic of Korea
• Retrospective Studies
• Survival Rate
• Young Adult